{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T11:24:40Z","timestamp":1769253880627,"version":"3.49.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"\u2018Construction and application of an anticancer drug knowledge graph based on a science popularization public account\u2019","award":["2024KP136"],"award-info":[{"award-number":["2024KP136"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Dasatinib was approved for treating pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. While its efficacy has been proven, comprehensive safety data in pediatric populations remain limited. This study utilizes data from the food and drug administration adverse event reporting system (FAERS) to evaluate and characterize adverse events (AEs) reported in pediatric patients treated with dasatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data from the FAERS between 2014 Q1 and 2024 Q4 were analyzed. Disproportionality analysis was performed to identify AEs reported in pediatric patients treated with dasatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 382 pediatric cases involving dasatinib were reported. The most frequent system organ classes included general disorders and administration site conditions, injury, poisoning, and procedural complications, and gastrointestinal disorders. Notably, previously unreported AEs such as hemorrhagic enterocolitis, lymphoid tissue hyperplasia, hydrocephalus, and hemorrhagic cystitis were identified, raising potential new safety concerns. Additionally, instances of off-label use were observed, particularly in regions where dasatinib is not recommended for pediatric patients, underscoring the importance of vigilant AEs monitoring to ensure patient safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study highlights the need for enhanced pharmacovigilance and proactive monitoring in pediatric patients receiving dasatinib to ensure treatment safety and improve clinical outcomes, and provides supporting evidence for the safe use of dasatinib in pediatric populations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jjco\/hyaf154","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T11:58:24Z","timestamp":1758110304000},"page":"40-47","source":"Crossref","is-referenced-by-count":1,"title":["Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7764-2792","authenticated-orcid":false,"given":"Yuanyuan","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College , No. 69 Dongxia North Road, Jinping District, Shantou 515041 , Guangdong,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihao","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College , No. 69 Dongxia North Road, Jinping District, Shantou 515041 , Guangdong,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongbo","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College , No. 69 Dongxia North Road, Jinping District, Shantou 515041 , Guangdong,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqiong","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College , No. 69 Dongxia North Road, Jinping District, Shantou 515041 , Guangdong,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4820-9320","authenticated-orcid":false,"given":"Yan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy of the Second Affiliated Hospital, Shantou University Medical College , No. 69 Dongxia North Road, Jinping District, Shantou 515041 , Guangdong,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2026012223580144600_ref1","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","article-title":"Germline mutations in predisposition genes in Pediatric cancer","volume":"373","author":"Zhang","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012223580144600_ref2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood.2023023153","article-title":"How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults","volume":"145","author":"Tran","year":"2025","journal-title":"Blood"},{"key":"2026012223580144600_ref3","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1126\/science.aaw4892","article-title":"Science and health for all children with cancer","volume":"363","author":"Lam","year":"2019","journal-title":"Science"},{"key":"2026012223580144600_ref4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","article-title":"Pediatric chronic myeloid leukemia is a unique disease that requires a different approach","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"2026012223580144600_ref5","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/nejm200004063421402","article-title":"Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"342","author":"Aric\u00f2","year":"2000","journal-title":"N Engl J Med"},{"key":"2026012223580144600_ref6","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1038\/leu.2012.134","article-title":"Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up","volume":"26","author":"Larson","year":"2012","journal-title":"Leukemia"},{"key":"2026012223580144600_ref7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"2026012223580144600_ref8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40265-016-0677-x","article-title":"Dasatinib: a review in chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia","volume":"77","author":"Keating","year":"2017","journal-title":"Drugs"},{"key":"2026012223580144600_ref9","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of Dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"2026012223580144600_ref10","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's oncology group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"2026012223580144600_ref11","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1200\/jco.2012.46.8280","article-title":"Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the innovative therapies for children with cancer consortium","volume":"31","author":"Zwaan","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026012223580144600_ref12","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"2026012223580144600_ref13","doi-asserted-by":"publisher","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther Adv Drug Saf"},{"key":"2026012223580144600_ref14","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"key":"2026012223580144600_ref15","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1016\/s2352-3026(23)00088-1","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger","year":"2023","journal-title":"Lancet Haematol"},{"key":"2026012223580144600_ref16","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1200\/jco.2017.75.9597","article-title":"Dasatinib in Pediatric patients with chronic myeloid Leukemia in chronic phase: results from a phase II trial","volume":"36","author":"Gore","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026012223580144600_ref17","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/bloodadvances.2020003759","article-title":"A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety","volume":"5","author":"Hijiya","year":"2021","journal-title":"Blood Adv"},{"key":"2026012223580144600_ref18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/pbc.22945","article-title":"Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy","volume":"56","author":"Hobernicht","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2026012223580144600_ref19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3947\/ic.2018.50.2.153","article-title":"Cytomegalovirus colitis during Dasatinib treatment for patients with hematologic malignancy: case series and literature review","volume":"50","author":"Choi","year":"2018","journal-title":"Infect Chemother"},{"key":"2026012223580144600_ref20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s15010-017-1105-1","article-title":"Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature","volume":"46","author":"Knoll","year":"2018","journal-title":"Infection"},{"key":"2026012223580144600_ref21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41572-024-00519-9","article-title":"Paediatric hydrocephalus","volume":"10","author":"Kahle","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026012223580144600_ref22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1365-2141.2010.08465.x","article-title":"Excellent response to dasatinib of childhood Philadelphia positive intracranial acute lymphoblastic leukaemia tumours","volume":"152","author":"Bhadri","year":"2011","journal-title":"Br J Haematol"},{"key":"2026012223580144600_ref23","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/pas.0000000000000488","article-title":"Dasatinib-related follicular hyperplasia: an underrecognized entity with characteristic morphology","volume":"39","author":"Ozawa","year":"2015","journal-title":"Am J Surg Pathol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/40\/64472994\/hyaf154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/1\/40\/64472994\/hyaf154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T04:58:07Z","timestamp":1769144287000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/1\/40\/8271051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2026,1,9]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaf154","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,10,2]]}}}